t0901317 and Metabolic-Syndrome

t0901317 has been researched along with Metabolic-Syndrome* in 2 studies

Reviews

1 review(s) available for t0901317 and Metabolic-Syndrome

Article	Year
[Role of LXRs in control of lipogenesis]. Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 2007, Volume: 52, Issue:13 Suppl Topics: Animals; DNA; DNA-Binding Proteins; Fatty Acids, Nonesterified; Humans; Hydrocarbons, Fluorinated; Ligands; Lipogenesis; Liver X Receptors; Metabolic Syndrome; Orphan Nuclear Receptors; Receptors, Cytoplasmic and Nuclear; Sterol Regulatory Element Binding Protein 1; Sulfonamides; Transcription, Genetic	2007

Article

Year

[Role of LXRs in control of lipogenesis].

Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 2007, Volume: 52, Issue:13 Suppl

Topics: Animals; DNA; DNA-Binding Proteins; Fatty Acids, Nonesterified; Humans; Hydrocarbons, Fluorinated; Ligands; Lipogenesis; Liver X Receptors; Metabolic Syndrome; Orphan Nuclear Receptors; Receptors, Cytoplasmic and Nuclear; Sterol Regulatory Element Binding Protein 1; Sulfonamides; Transcription, Genetic

2007

Other Studies

1 other study(ies) available for t0901317 and Metabolic-Syndrome

Article	Year
Identification of a lead pharmacophore for the development of potent nuclear receptor modulators as anticancer and X syndrome disease therapeutic agents. Bioorganic & medicinal chemistry letters, 2006, Aug-15, Volume: 16, Issue:16 A series of tetrahydroisoquinoline-N-phenylamide derivatives were designed, synthesized, and tested for their relative binding affinity and antagonistic activity against androgen receptor (AR). Compound 1b (relative binding affinity, RBA = 6.4) and 1h (RBA = 12.6) showed higher binding affinity than flutamide (RBA = 1), a potent AR antagonist. These two compounds also exerted optimal antagonistic activity against AR in reporter assays. The derivatives were also tested for their activities against another nuclear receptor, farnesoid x receptor (FXR), with most compounds acting as weak antagonists, however, compound 1h behaved as a FXR agonist with activity slightly less than that of chenodeoxycholic acid (CDCA), a natural FXR agonist. Topics: Antineoplastic Agents; Cell Line; Chemistry, Pharmaceutical; Chenodeoxycholic Acid; DNA-Binding Proteins; Drug Design; Genes, Reporter; Humans; Metabolic Syndrome; Models, Chemical; Models, Molecular; Neoplasms; Protein Binding; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Transcriptional Activation; Transfection; Two-Hybrid System Techniques	2006

Article

Year

Identification of a lead pharmacophore for the development of potent nuclear receptor modulators as anticancer and X syndrome disease therapeutic agents.

Bioorganic & medicinal chemistry letters, 2006, Aug-15, Volume: 16, Issue:16

A series of tetrahydroisoquinoline-N-phenylamide derivatives were designed, synthesized, and tested for their relative binding affinity and antagonistic activity against androgen receptor (AR). Compound 1b (relative binding affinity, RBA = 6.4) and 1h (RBA = 12.6) showed higher binding affinity than flutamide (RBA = 1), a potent AR antagonist. These two compounds also exerted optimal antagonistic activity against AR in reporter assays. The derivatives were also tested for their activities against another nuclear receptor, farnesoid x receptor (FXR), with most compounds acting as weak antagonists, however, compound 1h behaved as a FXR agonist with activity slightly less than that of chenodeoxycholic acid (CDCA), a natural FXR agonist.

Topics: Antineoplastic Agents; Cell Line; Chemistry, Pharmaceutical; Chenodeoxycholic Acid; DNA-Binding Proteins; Drug Design; Genes, Reporter; Humans; Metabolic Syndrome; Models, Chemical; Models, Molecular; Neoplasms; Protein Binding; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Transcriptional Activation; Transfection; Two-Hybrid System Techniques

2006